Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was down 5.6% during trading on Tuesday . The company traded as low as C$0.09 and last traded at C$0.09. Approximately 74,700 shares traded hands during mid-day trading, an increase of 6% from the average daily volume of 70,178 shares. The stock had previously closed at C$0.09.
Hemostemix Trading Down 5.6 %
The company has a market cap of C$7.41 million, a P/E ratio of -4.25 and a beta of 0.15. The business’s fifty day moving average is C$0.06 and its 200 day moving average is C$0.05.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Further Reading
- Five stocks we like better than Hemostemix
- 3 Grocery Stocks That Are Proving They Are Still Essential
- What’s Next After FOMC’s Aggressive Interest Rate Cuts?
- How Investors Can Find the Best Cheap Dividend Stocks
- Verizon Stock: 5G Boom and Robust Dividend Yield at Play
- What are earnings reports?
- 3 Stocks with Upgraded Ratings: Analysts Predict More Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
